Atrandi Biosciences, a Vilnius, Lithuania-based life sciences company advancing new single-cell analysis technology, raised $25M in Series A funding.
The round was led by Lux Capital, with participation from Vsquared Ventures, Practica Capital, Metaplanet and GRIDS Capital.
The company intends to use the funds to accelerate its expansion into the U.S. market, support the growth of its semi-permeable capsule (SPC) technology, and advance new product development to enable scientific discoveries.
Led by CEO Juozas Nainys, Atrandi Biosciences is empowering single-cell analysis with its patented semi-permeable capsule (SPC) technology, enabling single-cell multiomics. By simplifying complex workflows, it accelerates discoveries in cellular heterogeneity, clonal evolution, microbiome diversity, microbial ecology, and more.
Its flagship products include:
- Flux Microfluidic Device – A platform built for high-throughput single-cell isolation into Semi-Permeable Capsules (SPCs) at the push of a button.
- Onyx Droplet Generator – A microfluidic platform designed for high-throughput single-cell and single-molecule applications.
- Styx High-Throughput Screening Platform – A screening platform designed for efficient fluorescence-activated droplet sorting.
FinSMEs
19/02/2025